ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 357

Osteoporosis and Breast Cancer: Outcomes at a Specialized Osteoporosis Clinic Following a Structured Assessment

Juan Carlos Ordoñez1, Salvador López-Salguero1, Laura Ranieri1, Mariano Andrés1,2, Jose Ponce3 and Isabel Ibero1, 1RHEUMATOLOGY, HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE, Alicante, Spain, 2Departamento de Medicina Clínica, Universidad Miguel Hernández, Alicante, Spain, 3ONCOLOGY, HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE, Alicante, Spain

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Cancer treatments and osteoporosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis - Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:  Women with breast cancer are at an increased risk for the development of bone loss and osteoporosis mainly due to adjuvant therapies, such as aromatase inhibitors (AI). AI therapy fully suppresses estrogen synthesis, further exacerbating the increased bone resorption and leading to an excess fracture risk. Thus, a close monitoring of bone mineral metabolism is recommended in these cases. The aim of the present study was to analyze bone health status and clinical characteristics of women with breast cancer referred by oncologist to a specialized clinic and their outcomes during follow-up.

Methods:  Retrospective analysis of consecutive female patients with recent breast cancer (BC) and low bone mineral density (BMD) referred to the osteoporosis outpatient clinic for assessment, as agreed with oncologists. A descriptive analysis of epidemiological, clinical, laboratory, imaging, and dual energy x-ray absorptiometry (DEXA) data is presented, both at baseline and last visit. 95% confidence intervals (95%CI) were estimated for rate of fragility fractures (FF) at baseline and during follow-up.

Results:  A total number of 122 female patients have been assessed up to May 2016; median aged 60.9 (SD±10.6) years old, 91.5% postmenopausal. BC was non-methastasic in 89 (70.3%), and 89 (70.3%) patients were on aromatase inhibitors (66 on letrozole). At baseline, 26 patients (21.0%, 95CI% 20.9-21.1) had previous FF, mostly vertebral (13) or non-vertebral (9), and two cases had suffered from multiple FF. BMDs were at osteoporotic range at the lumbar spine and osteopenic at both the femoral neck and hip. Median 25-hydroxyvitamin D levels were 23.9ng/mL (p25-75 18.1-45.1) at baseline. Regarding antiosteoporotic therapies, bisphosphonates were prescribed in 62 cases (66.6%), denosumab in 16 (17.2%), and raloxifene in one case (1.0%); the others were only on calcium plus vitamin D supplementation. A total of 102 patients were followed a median of 1.5 years (0.8-2.5), and 20 (16%) discontinued controls. During follow-up, new FF occurred in nine patients (9.0%, 95%CI 8.9-9.1), that were vertebral in 6, non-vertebral in 2, both in one case, while no hip FF were detected.

Conclusion:  The outcomes of a structured assessment of female patients with BC and low BMD are reported here. Despite this, almost 10% of cases developed a new FF, highlighting the need for special attention to this singular, secondary form of osteoporosis.


Disclosure: J. C. Ordoñez, None; S. López-Salguero, None; L. Ranieri, None; M. Andrés, None; J. Ponce, None; I. Ibero, None.

To cite this abstract in AMA style:

Ordoñez JC, López-Salguero S, Ranieri L, Andrés M, Ponce J, Ibero I. Osteoporosis and Breast Cancer: Outcomes at a Specialized Osteoporosis Clinic Following a Structured Assessment [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/osteoporosis-and-breast-cancer-outcomes-at-a-specialized-osteoporosis-clinic-following-a-structured-assessment/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/osteoporosis-and-breast-cancer-outcomes-at-a-specialized-osteoporosis-clinic-following-a-structured-assessment/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology